Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9,806Revenue $M2,154Net Margin (%)15.8Z-Score7.0
Enterprise Value $M9,969EPS $2.1Operating Margin %19.4F-Score3
P/E(ttm))27.1Cash Flow Per Share $0Pre-tax Margin (%)20.3Higher ROA y-yN
Price/Book6.110-y EBITDA Growth Rate %31.8Quick Ratio1.5Cash flow > EarningsY
Price/Sales4.35-y EBITDA Growth Rate %46.8Current Ratio2.0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %17.8ROA % (ttm)16.2Higher Current Ratio y-yN
Dividend Yield %0.5Insider Buy (3m)0ROE % (ttm)24.7Less Shares Outstanding y-yN
Payout Ratio %13.0Shares Outstanding M170ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with RDY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
RDYKen Fisher 2014-06-30 Add0.13%$38.67 - $46.08
$ 57.5637%Add 62.43%3,773,114
RDYKen Fisher 2014-03-31 Add0.08%$39.5 - $47.4
$ 57.5633%Add 56.3%2,322,863
RDYKen Fisher 2013-06-30 Add0.04%$32.98 - $38.7
$ 57.5658%Add 48.42%1,283,605
RDYKen Fisher 2013-03-31 Add0.02%$32.03 - $36.57
$ 57.5668%Add 31.46%864,830
RDYKen Fisher 2012-09-30 Buy 0.05%$28.94 - $32.58
$ 57.5691%New holding, 604555 sh.604,555
RDYBrian Rogers 2007-09-30 Sold Out -0.33%$15.25 - $16.85
$ 57.56258%Sold Out0
RDYBrian Rogers 2007-06-30 Buy 0.33%$15.25 - $17.25
$ 57.56253%New holding, 4250000 sh.4,250,000
RDYMohnish Pabrai 2006-09-30 Sold Out -1.11%$13.55 - $16.04
$ 57.56276%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RDY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
RDY Ken Fisher 2014-09-303,994,8682.350.45+5.88%
Premium Most recent portfolio changes are included for Premium Members only!

RDY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about RDY :

    Quarterly/Annual Reports about RDY:

      News about RDY:

      Articles On GuruFocus.com
      Should You Buy Actavis? Mar 18 2014 
      Dr. Reddy’s Laboratories: Should Continue to Gain Market Share in Lucrative Markets May 25 2012 
      5 Mid-Cap Healthcare Dividend Stocks with Perfect Earnings Growth Dec 05 2011 
      Abbott Laboratories and the “India Cure” for the Ailing Pharmaceutical Industry May 26 2010 
      Dr. Reddy’s Q3 FY09 Revenue at Rs. 18,401 million, EBITDA at Rs. 3,453 million, PAT at Rs. 1,924 m Jan 20 2009 

      More From Other Websites
      Consumer Retail/Spending top the Lg Cap List... Nov 20 2014
      Dr. Reddy’s Announces the Launch of Over-the-Counter Fexofenadine Hydrochloride 60 mg and... Nov 20 2014
      Dr. Reddy’s Announces the Launch of Over-the-Counter Fexofenadine Hydrochloride 60 mg and... Nov 20 2014
      Upside For India's Tata, Dr. Reddy's, Korea's SK Telecom, China Rail Nov 18 2014
      Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation Nov 13 2014
      India: Ride The Investing Wave, Citi Says Nov 13 2014
      Dr. Reddy’s Q2 FY15 Financial Results Q2 FY15 Revenues at ?35.9 billion Q2 FY15 EBITDA at ?8.7... Nov 12 2014
      Could India's Sensex Rise 50% By 2016? Nov 11 2014
      Dr. Reddy's Laboratories: The Bridge to 2016 Nov 10 2014
      3 Drugs Stocks Pushing The Industry Higher Nov 07 2014
      Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y Oct 30 2014
      Dr. Reddy’s Q2 and H1 FY15 Financial Results Oct 29 2014
      Dr. Reddy’s Q2 and H1 FY15 Financial Results Oct 29 2014
      Why Indonesia Isn't India, Pakistan Isn't Emerging Oct 28 2014
      Dr. Reddy’s Announces the Launch of Sirolimus Tablets, 1 mg and 2 mg Oct 28 2014
      Dr. Reddy's to Release Q2 FY15 Results on October 29, 2014 Oct 17 2014
      Emerging Markets Monday In Review Oct 13 2014
      Sucampo Enters into Settlement Agreement for Amitiza Oct 13 2014
      Generics Firms Step Up Their Game In Branded Drugs Oct 06 2014
      Today's Market Thorns, Roses, and All Time Highs... Plus an Extra... Sep 25 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial